Lymphotoxin-β receptor activation by lymphotoxin-α 1β2 and LIGHT promotes tumor growth in an NFκB-dependent manner

International Journal of Cancer

Volumn 128, Issue 6, 2011, Pages 1363-1370

  Daller, Barbara ^a   Müsch, Werner ^a   Röhrl, Johann ^a   Tumanov, Alexei V ^b   Nedospasov, Sergei A ^b,c   Männel, Daniela N ^a   Schneider Brachert, Wulf ^a   Hehlgans, Thomas ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^c DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

Author keywords

CXCL2; lymphotoxin beta receptor activation; NF B signalling; tumor angiogenesis

Indexed keywords

CXCL2 CHEMOKINE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOTOXIN ALPHA BETA; LYMPHOTOXIN BETA RECEPTOR; PROTEIN LIGHT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CELL SURFACE; CELL VIABILITY; CONTROLLED STUDY; EPIGENETICS; EXPRESSION VECTOR; FEMALE; FIBROSARCOMA; GENE ACTIVATION; IN VITRO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR GROWTH;

ANIMALS; APOPTOSIS; B-LYMPHOCYTES; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CXCL2; FEMALE; FIBROSARCOMA; FLOW CYTOMETRY; LYMPHOTOXIN ALPHA1, BETA2 HETEROTRIMER; LYMPHOTOXIN BETA RECEPTOR; LYMPHOTOXIN-BETA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79551499618     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25456     Document Type: Article

References (35)

1. Force WR, Walter BN, Hession C, Tizard R, Kozak CA, Browning JL, Ware CF,. Mouse lymphotoxin-beta receptor. Molecular genetics, ligand binding, and expression. J Immunol 1995; 155: 5280-8.
2. Lipp M, Muller G,. Lymphoid organogenesis: getting the green light from RORgamma(t). Nat Immunol 2004; 5: 12-14.
3. Stopfer P, Mannel DN, Hehlgans T,. Lymphotoxin-beta receptor activation by activated T cells induces cytokine release from mouse bone marrow-derived mast cells. J Immunol 2004; 172: 7459-65.
4. Tamada K, Shimozaki K, Chapoval AI, Zhai Y, Su J, Chen SF, Hsieh SL, Nagata S, Ni J, Chen L,. LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol 2000; 164: 4105-10.
5. Bonizzi G, Karin M,. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25: 280-8.
6. Vallabhapurapu S, Karin M,. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009; 27: 693-733.
7. Dejardin E, Droin NM, Delhase M, Haas E, Cao Y, Makris C, Li ZW, Karin M, Ware CF, Green DR,. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 2002; 17: 525-35.
8. Hehlgans T, Pfeffer K,. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005; 115: 1-20.
9. Jiang X, Takahashi N, Matsui N, Tetsuka T, Okamoto T,. The NF-kappa B activation in lymphotoxin beta receptor signaling depends on the phosphorylation of p65 at serine. J Biol Chem 2003; 278: 919-26.
10. Luftig MA, Cahir-McFarland E, Mosialos G, Kieff E,. Effects of the NIK aly mutation on NF-kappaB activation by the Epstein-Barr virus latent infection membrane protein, lymphotoxin beta receptor, and CD40. J Biol Chem 2001; 276: 14602-6.
11. Banks TA, Rouse BT, Kerley MK, Blair PJ, Godfrey VL, Kuklin NA, Bouley DM, Thomas J, Kanangat S, Mucenski ML,. Lymphotoxin-alpha-deficient mice. Effects on secondary lymphoid organ development and humoral immune responsiveness. J Immunol 1995; 155: 1685-93.
12. De Togni P, Goellner J, Ruddle NH, Streeter PR, Fick A, Mariathasan S, Smith SC, Carlson R, Shornick LP, Strauss-Schoenberger J,. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 1994; 264: 703-7.
13. Futterer A, Mink K, Luz A, Kosco-Vilbois MH, Pfeffer K,. The lymphotoxin beta receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity 1998; 9: 59-70.
14. Hehlgans T, Stoelcker B, Stopfer P, Muller P, Cernaianu G, Guba M, Steinbauer M, Nedospasov SA, Pfeffer K, Mannel DN,. Lymphotoxin-beta receptor immune interaction promotes tumor growth by inducing angiogenesis. Cancer Res 2002; 62: 4034-40.
15. Browning JL, Miatkowski K, Sizing I, Griffiths D, Zafari M, Benjamin CD, Meier W, Mackay F,. Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines. J Exp Med 1996; 183: 867-78.
16. Lukashev M, LePage D, Wilson C, Bailly V, Garber E, Lukashin A, Ngam-ek A, Zeng W, Allaire N, Perrin S, Xu X, Szeliga K, et al. Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy Cancer Res. 2006; 66: 9617-24.
17. Dhawan P, Su Y, Thu YM, Yu Y, Baugher P, Ellis DL, Sobolik-Delmaire T, Kelley M, Cheung TC, Ware CF, Richmond A,. The lymphotoxin-beta receptor is an upstream activator of NF-kappaB-mediated transcription in melanoma cells. J Biol Chem 2008; 283: 15399-408.
18. Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, Kurrer MO, Bremer J, Iezzi G, Graf R, Clavien PA, Thimme R, Blum H, et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 2009; 16: 295-308.
19. Bergers G, Benjamin LE,. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-10.
20. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell 2000; 100: 57-70.
21. Keane MP, Belperio JA, Moore TA, Moore BB, Arenberg DA, Smith RE, Burdick MD, Kunkel SL, Strieter RM,. Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. J Immunol 1999; 162: 5511-8.
22. Kollmar O, Menger MD, Schilling MK,. Macrophage inflammatory protein-2 contributes to liver resection-induced acceleration of hepatic metastatic tumor growth. World J Gastroenterol 2006; 12: 858-67.
23. Scheu S, Alferink J, Potzel T, Barchet W, Kalinke U, Pfeffer K,. Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis. J Exp Med 2002; 195: 1613-24.
24. Tumanov AV, Grivennikov SI, Shakhov AN, Rybtsov SA, Koroleva EP, Takeda J, Nedospasov SA, Kuprash DV,. Dissecting the role of lymphotoxin in lymphoid organs by conditional targeting. Immunol Rev 2003; 195: 106-16.
25. Stoelcker B, Ruhland B, Hehlgans T, Bluethmann H, Luther T, Mannel DN,. Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature. Am J Pathol 2000; 156: 1171-6.
26. O'Reilly MS, Holmgren L, Chen C, Folkman J,. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2: 689-92.
27. Schneider-Brachert W, Tchikov V, Neumeyer J, Jakob M, Winoto-Morbach S, Held-Feindt J, Heinrich M, Merkel O, Ehrenschwender M, Adam D, Mentlein R, Kabelitz D, et al. Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity 2004; 21: 415-28.
28. Hehlgans T, Muller P, Stopfer P, Mannel DN,. Activation of the lymphotoxin-beta receptor induces NFkappaB-dependent interleukin-6 and MIP-2 secretion in mouse fibrosarcoma cells. Eur Cytokine Netw 2003; 14: 103-7.
29. Dejardin E,. The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem Pharmacol 2006; 72: 1161-79.
30. Matsushima A, Kaisho T, Rennert PD, Nakano H, Kurosawa K, Uchida D, Takeda K, Akira S, Matsumoto M,. Essential role of nuclear factor (NF)-kappaB-inducing kinase and inhibitor of kappaB (IkappaB) kinase alpha in NF-kappaB activation through lymphotoxin beta receptor, but not through tumor necrosis factor receptor I. J Exp Med 2001; 193: 631-6.
31. Basseres DS, Baldwin AS,. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006; 25: 6817-30.
32. Widmer U, Manogue KR, Cerami A, Sherry B,. Genomic cloning and promoter analysis of macrophage inflammatory protein (MIP)-2, MIP-1 alpha, and MIP-1 beta, members of the chemokine superfamily of proinflammatory cytokines. J Immunol 1993; 150: 4996-5012.
33. Driscoll KE, Hassenbein DG, Howard BW, Isfort RJ, Cody D, Tindal MH, Suchanek M, Carter JM,. Cloning, expression, and functional characterization of rat MIP-2: a neutrophil chemoattractant and epithelial cell mitogen. J Leukoc Biol 1995; 58: 359-64.
34. Holtmann H, Winzen R, Holland P, Eickemeier S, Hoffmann E, Wallach D, Malinin NL, Cooper JA, Resch K, Kracht M,. Induction of interleukin-8 synthesis integrates effects on transcription and mRNA degradation from at least three different cytokine- or stress-activated signal transduction pathways. Mol Cell Biol 1999; 19: 6742-53.
35. Lovas A, Radke D, Albrecht D, Yilmaz ZB, Moller U, Habenicht AJ, Weih F,. Differential RelA- and RelB-dependent gene transcription in LTbetaR-stimulated mouse embryonic fibroblasts. BMC Genomics 2008; 9: 606.